The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity.
Poly(ethylene glycol) (PEG)-derivatized liposome vehicles improve antitumor effectiveness of entrapped anthracyclines and vinca alkaloids. However, the plasma clearance of entrapped vincristine is substantially faster than the lipid phase or other entrapped aqueous markers, suggesting leakage out of the liposome during transit in the blood compartment. We tested the effect of altering the drug's in vivo leakage rate on pharmacokinetics, toxicity, and antitumor activity of entrapped drug in rodent models. Suramin, heparin, and dextran sulfate were tested for their ability to produce a precipitable complex in vitro. PEG-derivatized liposomes were prepared with the complexing agent inside, and vincristine was driven inside using an ammonium gradient. The resulting preparations were found to have plasma distribution half-lives significantly longer than the formulation without a complex-forming agent. There was no increase in acute lethality, and in the case of the suramin-vincristine complex, the acute lethality was significantly reduced at the highest does level. Anti-tumor activity against the mouse mammary carcinoma MC2 was tested in a multiple-dose study. Free vincristine did not affect the tumor growth rate significantly, but at the same dose level all PEG-coated liposome formulations inhibited tumor growth markedly. The suramin containing formulation was as effective as the formulation lacking polyanion, but the heparin and dextran sulfate containing formulations were less effective. Thus, compounds which form insoluble complexes with vincristine alter in vivo plasma distribution phase pharmacokinetics without increasing acute lethality, but without a corresponding increase in anti-tumor activity.
Zhu
G
G
SEQUUS Pharmaceuticals, Inc., Menlo Park, CA 94025, USA.
Oto
E
E
Vaage
J
J
Quinn
Y
Y
Newman
M
M
Engbers
C
C
Uster
P
P
D000818:Animals; D000838:Anions; D000925:Anticoagulants; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity*; D016264:Dextran Sulfate; D004337:Drug Carriers; D005260:Female; D006493:Heparin; D007275:Injections, Intravenous; D008081:Liposomes; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism*; D051379:Mice; D008813:Mice, Inbred ICR; D011092:Polyethylene Glycols; D051381:Rats; D017207:Rats, Sprague-Dawley; D013498:Suramin; D014750:Vincristine / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity*
D000838:Anions; D000925:Anticoagulants; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008081:Liposomes; D011092:Polyethylene Glycols; D014750:Vincristine; D013498:Suramin; D006493:Heparin; D016264:Dextran Sulfate